[Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
Traitement des syndromes parkinsoniens par la L. DOPA et par l'association L. DOPA-inhibiteur de la decarboxylse.